Dingsu Bao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dingsu Bao has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Huan Liu
Department of Orthopaedics, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University
3 shared publications Shengqiang Zeng
Department of Orthopedics, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China
2 shared publications- Shijie Fu
Department of Orthopedics, Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, China
2 shared publications Zhenhong He
Department of Orthopedics, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China
2 shared publicationsBo Qin
Department of Orthopedics, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China
1 shared publication- Bo Qin
Department of Orthopedics, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan 646600, China
1 shared publication
Latest Publications
- Open Access
- 1 December 2025
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 21 (1)
TGF-β signaling in heterotopic ossification: the pathogenesis and the target for its treatment
Heterotopic Ossification (HO) is a complex and multifactorial pathological process characterized by abnormal bone production in areas outside the skeletal
- 1 December 2025
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 21 (1)
Open AccessTGF-β signaling in heterotopic ossification: the pathogenesis and the target for its treatment
Heterotopic Ossification (HO) is a complex and multifactorial pathological process characterized by abnormal bone production in areas outside the skeletal
- Open Access
- 1 November 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 85, 967-1008
Tetrahedral framework nucleic acids: Nanokeys unlocking a new era of precision biomedicine
- 1 November 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 85, 967-1008
Open AccessTetrahedral framework nucleic acids: Nanokeys unlocking a new era of precision biomedicine
- Open Access
- 15 April 2025
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 20 (1) , 1-12
Investigation on the role of Icariin in tendon injury repair: focusing on tendon stem cell differentiation
Tendon injury is a common and frequent disease in the field of sports medicine, and tendon repair after injury is a common clinical difficulty. Repair strategy based on tendon stem cells (TDSCs) therapy is considered a promising therapeutic option for the treatment of tendon injuries. Icariin (ICA) has been shown to be an effective herbal monomer for the treatment of tendon-bone healing and may be effective in the repair of tendon injuries. In vitro, TDSCs isolated from C57 mice were treated with ICA (0.01–100 µM) to assess proliferation (CCK-8 assay) and tendonogenic differentiation (qRT-PCR). In vivo, 42 C57 mice with surgically induced patellar tendon defects were randomized into three groups (n = 14/group): (1) 20 mg/kg ICA, (2) 40 mg/kg ICA, and (3) control group (DMSO), administered intraperitoneally for 14 days. Half of each group (n = 7) underwent histopathological (hematoxylin-eosin staining, Masson staining) and molecular (qRT-PCR) analyses at 2 and 4 weeks post-surgery. In vitro, after 7 days of ICA intervention in TDSC, the expression of Mohawk (MKX), Scleraxis (SCX), fibromodulin (FMOD), and Tenomodulin (TNC) were higher in the ICA group than in the control group. In vivo, the expression of MKX, SCX, FMOD, and TNC was higher in the 20 mg/kg ICA group and 40 mg/kg ICA group than in the control group at 2 and 4 weeks after surgery. Histological evaluation revealed superior tendon repair in both ICA-treated groups compared to controls at both 2 and 4 weeks postoperative intervals. The 20 mg/kg ICA group demonstrated a significant enhancement in tissue continuity and collagen fiber organization, exhibiting greater defect filling, fewer interstitial gaps, and reduced vascular infiltration. In contrast, control specimens exhibited disorganized collagen architecture with prominent interstitial gaps. The 40 mg/kg ICA group showed intermediate repair outcomes between the 20 mg/kg ICA and control groups. ICA can improve tendon injury repair by enhancing tendonogenic differentiation of TDSC.
- 15 April 2025
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 20 (1) , 1-12
Open AccessInvestigation on the role of Icariin in tendon injury repair: focusing on tendon stem cell differentiation
Tendon injury is a common and frequent disease in the field of sports medicine, and tendon repair after injury is a common clinical difficulty. Repair strategy based on tendon stem cells (TDSCs) therapy is considered a promising therapeutic option for the treatment of tendon injuries. Icariin (ICA) has been shown to be an effective herbal monomer for the treatment of tendon-bone healing and may be effective in the repair of tendon injuries. In vitro, TDSCs isolated from C57 mice were treated with ICA (0.01–100 µM) to assess proliferation (CCK-8 assay) and tendonogenic differentiation (qRT-PCR). In vivo, 42 C57 mice with surgically induced patellar tendon defects were randomized into three groups (n = 14/group): (1) 20 mg/kg ICA, (2) 40 mg/kg ICA, and (3) control group (DMSO), administered intraperitoneally for 14 days. Half of each group (n = 7) underwent histopathological (hematoxylin-eosin staining, Masson staining) and molecular (qRT-PCR) analyses at 2 and 4 weeks post-surgery. In vitro, after 7 days of ICA intervention in TDSC, the expression of Mohawk (MKX), Scleraxis (SCX), fibromodulin (FMOD), and Tenomodulin (TNC) were higher in the ICA group than in the control group. In vivo, the expression of MKX, SCX, FMOD, and TNC was higher in the 20 mg/kg ICA group and 40 mg/kg ICA group than in the control group at 2 and 4 weeks after surgery. Histological evaluation revealed superior tendon repair in both ICA-treated groups compared to controls at both 2 and 4 weeks postoperative intervals. The 20 mg/kg ICA group demonstrated a significant enhancement in tissue continuity and collagen fiber organization, exhibiting greater defect filling, fewer interstitial gaps, and reduced vascular infiltration. In contrast, control specimens exhibited disorganized collagen architecture with prominent interstitial gaps. The 40 mg/kg ICA group showed intermediate repair outcomes between the 20 mg/kg ICA and control groups. ICA can improve tendon injury repair by enhancing tendonogenic differentiation of TDSC.
- Open Access
- 17 January 2024
- Published by Elsevier in Journal of Advanced Research
- Vol. 67, 361-372
Advances focusing on the application of decellularization methods in tendon-bone healing
- 17 January 2024
- Published by Elsevier in Journal of Advanced Research
- Vol. 67, 361-372
Open AccessAdvances focusing on the application of decellularization methods in tendon-bone healing
- Open Access
- 15 November 2023
- Published by Elsevier in Journal of Advanced Research
- Vol. 64, 155-169
Engineered exosomes: a promising strategy for tendon-bone healing
- 15 November 2023
- Published by Elsevier in Journal of Advanced Research
- Vol. 64, 155-169
Open AccessEngineered exosomes: a promising strategy for tendon-bone healing